Links

Homepage

Stock List

Search by Ticker

News

Login

Exelixis (NASDAQ:EXEL)
Stock Analysis

EXEL23.45
▼ -1.01%-0.24

Stock Analysis

The following stock analysis is based on 8 years of data (i.e. since Aug 03, 2012). All the stock history has been downloaded.

Stock Exchange

Exelixis trades on the NasdaqGS exchange in USD dollars.

Sector

It is in the sector.

Current Status of Exelixis

It is currently trading at $23.45 ($23.69 the previous day).

Financials

The next reporting date is in 2 days (2020 08 07).

CNN estimates profits for the upcoming quarter will be $0.12 per share ($226.2M). The current Canada / US exchange rate is 1.32937.



Over the past 12 months, $0 worth of shares have been purchased and $39294049 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is 28.4% per year assuming steady exponential growth. The actual 5 year average is 70.8. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year20.020085227273-0.4- Below Average
2 year20.108447488584-18.9- Below Average
3 year24.79619246861929.7- Below Average
4 year19.111457489879223+ Above Average
5 year5.9164528301887120.6+ Above Average
Exelixis is projected by analysts to get to $30.00 within the next 12 months (27.9%), but preticted targets range from as high as $40.00 (70.6%) and as low as $22(-6.2%).

Risk

The worst drop it has had in recent years is -84.3%. It has a up and down shape to the stock curve, which means the stock can have significant gains followed by losses. Good for day trading, but needs to be watched if held for any significant amount of time.

Stock shape test

DAYS AG0PRICE
1025.08DROPPING
3022.88RISING
6024.27DROPPING
15019.89RISING
36520.39DROPPING
80020.84DROPPING
120020.98DROPPING
16003.76RISING
20002.16RISING


With an average increase of 28.4% year over year, if Exelixis is bought at the worst time, Stockmarketizer analysts estimate it will take 35.6 months before the stock will recover to the original purchase price. The P/E value is 25.22.

Tradingview BuySell Widget

Yahoo News Feed

Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for

Thu, 30 Jul 2020 16:33:04 Exelixis (EXEL) doesnand't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.... Read Full Article

Exelixis to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020

Wed, 29 Jul 2020 20:05:00 Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 after the markets close. At 5:30 p.m. EDT / 2:30 p.m. PDT, Exelixis management will host a conference call and webcast to discuss ...... Read Full Article

Will Exelixis (EXEL) Gain on Rising Earnings Estimates?

Thu, 23 Jul 2020 16:20:04 Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.... Read Full Article

EXEL vs. RGEN: Which Stock Should Value Investors Buy Now?

Wed, 22 Jul 2020 15:40:03 EXEL vs. RGEN: Which Stock Is the Better Value Option?... Read Full Article

Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive?

Tue, 21 Jul 2020 16:10:04 Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.... Read Full Article

Exelixis Starts Study on Cabometyx Combo in Kidney Cancer

Tue, 21 Jul 2020 14:00:02 Exelixis (EXEL) initiates CONTACT-03, a global phase III pivotal study of Cabometyx (cabozantinib) in combination with Rocheand's Tecentriq.... Read Full Article

Could The Exelixis, Inc. (NASDAQ:EXEL) Ownership Structure Tell Us Something Useful?

Mon, 20 Jul 2020 16:43:21 If you want to know who really controls Exelixis, Inc. (NASDAQ:EXEL), then youand'll have to look at the makeup of its...... Read Full Article

Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma

Mon, 20 Jul 2020 12:00:00 Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with inoperable, locally advanced or metastatic renal cell carcinoma (RCC) who progressed during or following ...... Read Full Article

Did Hedge Funds Make The Right Call On Exelixis, Inc. (EXEL) ?

Mon, 13 Jul 2020 14:45:29 We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional ...... Read Full Article

2 Stocks to Buy if Youand're Worried About Another Market Crash

Fri, 10 Jul 2020 11:16:00 Here are two stocks that might do just that: Exelixis (NASDAQ: EXEL) and Netflix (NASDAQ: NFLX). Its revenue largely depends on just one product: Cabometyx, a tyrosine kinase inhibitor (TKI) that specifically targets cancer cells. This cancer drug is approved ...... Read Full Article

Got $3,000? 3 Growth Stocks You Wonand't Regret Buying

Fri, 10 Jul 2020 09:51:00 Although stock market corrections are part of the investing cycle, no investor, tenured or not, could have been prepared for what 2020 has offered. In about a four-month time span, the stock market has crammed in about a decade's worth of ...... Read Full Article

5 Booming Biotech Stocks to Buy

Fri, 03 Jul 2020 16:36:32 These five biotech stocks have already gone on heaters of 30% or more in 2020, and all of them still have plenty of upside to spare.... Read Full Article

Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer

Tue, 30 Jun 2020 12:00:00 Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with metastatic castration-resistant prostate cancer (CRPC) who have been previously treated with one novel hormonal ...... Read Full Article

Exelixis (EXEL) in Focus: Stock Moves 7.6% Higher

Tue, 23 Jun 2020 03:02:03 Exelixis (EXEL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.... Read Full Article

Exelixis to Webcast Virtual Fireside Chat as Part of the BofA Securities Napa Biopharma Conference on June 24, 2020

Thu, 18 Jun 2020 20:05:00 Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will participate in a fireside chat as part of the virtual BofA Securities Napa Biopharma Conference on Wednesday, June 24, 2020 at 3:30 ...... Read Full Article

3 Stocks Growing Capex Fast

Wed, 17 Jun 2020 17:42:02 Large spending to improve fixed assets may anticipate growth Continue reading...... Read Full Article

Hedge Funds Going Back and Forth About Exelixis, Inc. (EXEL)

Fri, 12 Jun 2020 14:15:56 The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and ...... Read Full Article

Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer

Thu, 11 Jun 2020 12:00:00 Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-01, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with an immune ...... Read Full Article

Exelixis (EXEL) Down 11.5% Since Last Earnings Report: Can It Rebound?

Thu, 04 Jun 2020 15:31:03 Exelixis (EXEL) reported earnings 30 days ago. Whatand's next for the stock? We take a look at earnings estimates for some clues.... Read Full Article
<